WO2015114452A3 - Composés antibactériens - Google Patents

Composés antibactériens Download PDF

Info

Publication number
WO2015114452A3
WO2015114452A3 PCT/IB2015/000177 IB2015000177W WO2015114452A3 WO 2015114452 A3 WO2015114452 A3 WO 2015114452A3 IB 2015000177 W IB2015000177 W IB 2015000177W WO 2015114452 A3 WO2015114452 A3 WO 2015114452A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymyxin
bacterial infections
gram
antibacterial combinations
antibacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2015/000177
Other languages
English (en)
Other versions
WO2015114452A2 (fr
Inventor
Ian Collins
David John Haydon
Helena THOMAIDES-BREARS
James T Palmer
Christopher James Lunniss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biota Europe Ltd
Original Assignee
Biota Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014900308A external-priority patent/AU2014900308A0/en
Priority to US15/116,150 priority Critical patent/US20170007615A1/en
Priority to BR112016018048A priority patent/BR112016018048A2/pt
Priority to EP15708045.8A priority patent/EP3102203A2/fr
Priority to AU2015212495A priority patent/AU2015212495A1/en
Priority to KR1020167024427A priority patent/KR20160115986A/ko
Priority to HK17105756.4A priority patent/HK1232135A1/zh
Priority to MX2016010057A priority patent/MX2016010057A/es
Application filed by Biota Europe Ltd filed Critical Biota Europe Ltd
Priority to SG11201606332PA priority patent/SG11201606332PA/en
Priority to CN201580018631.9A priority patent/CN106170294A/zh
Priority to JP2016567168A priority patent/JP2017504662A/ja
Priority to CA2938459A priority patent/CA2938459A1/fr
Publication of WO2015114452A2 publication Critical patent/WO2015114452A2/fr
Publication of WO2015114452A3 publication Critical patent/WO2015114452A3/fr
Priority to IL247019A priority patent/IL247019A0/en
Priority to PH12016501532A priority patent/PH12016501532A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne une nouvelle combinaison de composés, leur utilisation en tant qu'agents antibactériens, des compositions les comprenant et des méthodes pour traiter ou prévenir des infections bactériennes, plus particulièrement, des infections bactériennes provoquées par des pathogènes Gram-négatifs et/ou des bactéries Gram-négatives résistantes aux médicaments.
PCT/IB2015/000177 2014-02-03 2015-02-03 Composés antibactériens Ceased WO2015114452A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CA2938459A CA2938459A1 (fr) 2014-02-03 2015-02-03 Composes antibacteriens
SG11201606332PA SG11201606332PA (en) 2014-02-03 2015-02-03 Antibacterial combinations comprising polymyxin
EP15708045.8A EP3102203A2 (fr) 2014-02-03 2015-02-03 Composés antibactériens
AU2015212495A AU2015212495A1 (en) 2014-02-03 2015-02-03 Antibacterial combinations comprising polymyxin
KR1020167024427A KR20160115986A (ko) 2014-02-03 2015-02-03 폴리믹신을 포함하는 항균성 조합
HK17105756.4A HK1232135A1 (zh) 2014-02-03 2015-02-03 含多粘菌素的抗细菌组合
MX2016010057A MX2016010057A (es) 2014-02-03 2015-02-03 Compuestos antibacterianos.
US15/116,150 US20170007615A1 (en) 2014-02-03 2015-02-03 Antibacterial Compounds
CN201580018631.9A CN106170294A (zh) 2014-02-03 2015-02-03 含多粘菌素的抗细菌组合
JP2016567168A JP2017504662A (ja) 2014-02-03 2015-02-03 ポリミキシンを含む抗菌剤の組合せ
BR112016018048A BR112016018048A2 (pt) 2014-02-03 2015-02-03 Método para o tratamento ou prevenção de uma infecção bacteriana, uso de um inibidor de topoisomerase tipo ii bacteriana em combinação com uma polimixina ou derivado de polimixina no tratamento ou prevenção de uma infecção bacteriana, uso de um inibidor de topoisomerase tipo ii bacteriana em combinação com uma polimixina ou derivado de polimixina na preparação de um medicamento para o tratamento ou prevenção de uma infecção bacteriana, método para melhorar a atividade antibacteriana de um inibidor de topoisomerase tipo ii bacteriana, método para melhorar a eficácia bactericida de um inibidor de topoisomerase tipo ii bacteriana, composição, agente antibacteriano, processo, e, composto
IL247019A IL247019A0 (en) 2014-02-03 2016-07-31 Antibacterial combinations containing polymyxin
PH12016501532A PH12016501532A1 (en) 2014-02-03 2016-08-03 Antibacterial combinations comprising polymyxin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2014900308 2014-02-03
AU2014900308A AU2014900308A0 (en) 2014-02-03 Antibacterial compounds
AU2014902238 2014-06-12
AU2014902238A AU2014902238A0 (en) 2014-06-12 Antibacterial compounds

Publications (2)

Publication Number Publication Date
WO2015114452A2 WO2015114452A2 (fr) 2015-08-06
WO2015114452A3 true WO2015114452A3 (fr) 2015-11-12

Family

ID=52627536

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/000177 Ceased WO2015114452A2 (fr) 2014-02-03 2015-02-03 Composés antibactériens

Country Status (14)

Country Link
US (1) US20170007615A1 (fr)
EP (1) EP3102203A2 (fr)
JP (1) JP2017504662A (fr)
KR (1) KR20160115986A (fr)
CN (1) CN106170294A (fr)
AU (1) AU2015212495A1 (fr)
BR (1) BR112016018048A2 (fr)
CA (1) CA2938459A1 (fr)
HK (1) HK1232135A1 (fr)
IL (1) IL247019A0 (fr)
MX (1) MX2016010057A (fr)
PH (1) PH12016501532A1 (fr)
SG (1) SG11201606332PA (fr)
WO (1) WO2015114452A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019057946A1 (fr) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag Composés aromatiques multi-cycliques utilisés en tant qu'inhibiteurs du facteur d
US11897859B1 (en) 2023-03-09 2024-02-13 King Faisal University Coumarin compounds as antibacterial agents
US11773084B1 (en) 2023-04-14 2023-10-03 King Faisal University 4-arylamino-2-(6-indolylamino)pyrimidine compounds as antibacterial agents
US11891362B1 (en) 2023-04-14 2024-02-06 King Faisal University N2,N4-disubstituted pyrimidine-2,4-diamine compounds as antibacterial agents
CN118620800B (zh) * 2024-08-08 2024-11-12 中国兽医药品监察所 一株鼻疽伯克霍尔德氏菌及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2018864A1 (fr) * 2007-07-23 2009-01-28 Biomet Deutschland GmbH Composition pharmaceutique, substrat comprenant une composition pharmaceutique et utilisation d'une composition pharmaceutique
US20120184741A1 (en) * 2011-01-14 2012-07-19 Vertex Pharmaceuticals Incorporated Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-(1-hydroxy-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea
WO2012177707A1 (fr) * 2011-06-20 2012-12-27 Vertex Pharmaceuticals Incorporated Esters phosphoriques d'inhibiteurs de gyrases et de topoisomérases
WO2013091011A1 (fr) * 2011-12-21 2013-06-27 Biota Europe Ltd Composés hétérocycliques d'urée
US20130252938A1 (en) * 2012-03-22 2013-09-26 Biota Europe Ltd. Antibacterial Compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1251849A1 (fr) 2000-01-18 2002-10-30 Vertex Pharmaceuticals Incorporated Inhibiteurs de la gyrase et utilisations de ces derniers
AU782883B2 (en) 2000-01-18 2005-09-08 Vertex Pharmaceuticals Incorpoated Gyrase inhibitors and uses thereof
MY138797A (en) 2000-12-15 2009-07-31 Vertex Pharma Bacterial gyrase inhibitors and uses thereof
MXPA04012628A (es) 2002-06-13 2005-03-23 Patricia Olivershaffer DERIVADOS Y COMPUESTOS RELACIONADOS DEL áCIDO 2-UREIDO-6-HETEROARIL-3H-BENZOIMIDAZOL-4-CARBOXILICO COMO INHIBIDORES DE GIRASA Y/O TOPOISOMERASA IV PARA EL TRATAMIENTO DE INFECCIONES BACTERIALES.
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
US7569591B2 (en) 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8394803B2 (en) 2005-11-07 2013-03-12 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
GB0724349D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
RU2010123003A (ru) 2007-11-07 2011-12-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Способы получения и промежуточные соединения для получения аминобензимидазолмочевин
AU2008335409A1 (en) 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Solid forms of 1-ethyl-3-(5-(5-fluoropyridin-3-yl)-7-(pyrimidin-2-yl)-1H-benzo[d] imidazol-2-yl)urea
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
WO2011032050A2 (fr) 2009-09-11 2011-03-17 Trius Therapeutics, Inc. Inhibiteurs de gyrase
US9181234B2 (en) 2010-10-08 2015-11-10 Biota Europe Ltd. Antibacterial compounds
RU2625305C2 (ru) 2011-01-14 2017-07-13 Сперо Тринем, Инк. Твердые формы ингибитора гиразы (r)-1-этил-3-[6-фтор-5[2-(1-гидрокси-1-метил-этил) пиримидин-5-ил]-7-(тетрагидрофуран-2-ил)-1н-бензимидазол-2-ил] мочевины
JP6085829B2 (ja) 2011-01-14 2017-03-01 スペロ トリネム， インコーポレイテッド ピリミジンジャイレースおよびトポイソメラーゼｉｖ阻害剤
PT2663556E (pt) 2011-01-14 2014-11-27 Vertex Pharma Processo de fabrico de inibidores de girase e topoisomerase iv
PH12013501800A1 (en) 2011-03-15 2013-10-14 L Livermore Nat Security Llc Tricyclic gyrase inhibitors
US9018216B2 (en) 2012-07-18 2015-04-28 Vertex Pharmaceuticals Incorporated Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
WO2014014845A1 (fr) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Thérapie combinée comprenant de la 1-éthyl-3[5-[-2-{1-hydroxy-1-méthyl-éthyl}pyrimidin-5-yl]-7-(tétrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urée et ses dérivés pour traiter des maladies mycobactériennes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2018864A1 (fr) * 2007-07-23 2009-01-28 Biomet Deutschland GmbH Composition pharmaceutique, substrat comprenant une composition pharmaceutique et utilisation d'une composition pharmaceutique
US20120184741A1 (en) * 2011-01-14 2012-07-19 Vertex Pharmaceuticals Incorporated Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-(1-hydroxy-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea
WO2012177707A1 (fr) * 2011-06-20 2012-12-27 Vertex Pharmaceuticals Incorporated Esters phosphoriques d'inhibiteurs de gyrases et de topoisomérases
WO2013091011A1 (fr) * 2011-12-21 2013-06-27 Biota Europe Ltd Composés hétérocycliques d'urée
US20130252938A1 (en) * 2012-03-22 2013-09-26 Biota Europe Ltd. Antibacterial Compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. E. SOBIESZCZYK: "Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 54, no. 2, 1 July 2004 (2004-07-01), pages 566 - 569, XP055181729, DOI: 10.1093/jac/dkh369 *

Also Published As

Publication number Publication date
CN106170294A (zh) 2016-11-30
BR112016018048A2 (pt) 2017-08-08
MX2016010057A (es) 2017-04-27
HK1232135A1 (zh) 2018-01-05
EP3102203A2 (fr) 2016-12-14
US20170007615A1 (en) 2017-01-12
PH12016501532A1 (en) 2016-10-03
WO2015114452A2 (fr) 2015-08-06
SG11201606332PA (en) 2016-09-29
JP2017504662A (ja) 2017-02-09
IL247019A0 (en) 2016-09-29
CA2938459A1 (fr) 2015-08-06
KR20160115986A (ko) 2016-10-06
AU2015212495A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
EA201691766A1 (ru) Органические соединения, являющиеся монобактамами, для лечения бактериальных инфекций
AU2012302022A8 (en) Antibacterial compounds and methods for use
WO2017017631A3 (fr) Agents thérapeutiques antibactériens et agents prophylactiques
NZ724798A (en) Polymyxin derivatives as antimicrobial compounds
PH12016502436A1 (en) Anti-infective compounds
WO2013122888A3 (fr) Méthodes de traitement d'infections bactériennes
WO2016108045A3 (fr) Composés antimicrobiens, compositions et méthodes associées
HK1199693A1 (en) Antibacterial compounds and methods for use
MY188541A (en) Besifloxacin for the treatment of resistant acne
PH12019500360A1 (en) Antibiotic compounds
SG11201700621XA (en) Antibiotic compositions for treating bacterial infections
MX2018015125A (es) Nuevos compuestos antibacterianos.
WO2015110969A3 (fr) Composés contenant de l'azote et leur utilisation
AU2015352440B2 (en) Compounds
EP4268897A3 (fr) Composés de minocycline pour la défense biologique
HK1245257A1 (zh) 具有广谱活性的抗菌化合物
PH12018500358A1 (en) Compounds for use in an antibacterial applications
WO2017218922A3 (fr) Composés et méthodes pour le traitement d'infections bactériennes
PH12019502509A1 (en) Compounds and methods for treating bacterial infections
PH12016501532A1 (en) Antibacterial combinations comprising polymyxin
HK1243951A1 (zh) 抗微生物组合和其在治疗微生物感染中的用途
EP3273797A4 (fr) Composition inhibant des bactéries pathogènes gram-positives
EP3330275A4 (fr) Nouvel antibiotique aminoglycosidique efficace contre les bactéries résistantes à plusieurs médicaments
WO2015024021A3 (fr) Composés antibactériens
PH12015500518A1 (en) Tricyclic tetrahydroquinoline antibacterial agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15708045

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 247019

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2938459

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2016567168

Country of ref document: JP

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2015708045

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 15116150

Country of ref document: US

Ref document number: 2015708045

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12016501532

Country of ref document: PH

Ref document number: MX/A/2016/010057

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016018048

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2015212495

Country of ref document: AU

Date of ref document: 20150203

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20167024427

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016135712

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112016018048

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160803